About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01074970

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)or BRCA1/2 Mutations

Study identifier: NCT01074970
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

PF-01367338 (Clovis)

Eligibility:

  • Open to women with stage I-III breast cancer
  • Open to women with a BRCA mutation or women with Triple Negative Breast Cancer
  • This study is open to women who received standard neoadjuvant therapy for breast cancer but still have substantial residual disease at the time of surgery.

Type of study:

Phase II, randomized trial

Treatment:

Women who have already received neoadjuvant chemotherapy and have residual disease are randomized to receive the chemotherapy cisplatinum with or without the PARP Inhibitor PF-01367338.

Study sites:

Colorado

University of Colorado Cancer Center, Clinical Investigations Core
Aurora,CO80045
Contact: Sarah Witowsk 720-848-067

Florida

University of Miami, Sylvester Comprehensive Cancer Center
Miami, Florida 33136

Contact:  Olga Machado-Aguero RN 305-243-9811

Contact:  Eugene Ahn MD 305-243-6626

Indiana

Fort Wayne Onc & Hem, Inc        
Fort Wayne, Indiana, 46815
Contact: Sreenivasa Nattam, M..     260-484-8830       
Contact: Lesllie Edgar, R.N.     260-484-8830     ledgar@fwmoh.com

Indiana University Cancer Center              
Indianapolis, Indiana, 46202
Contact: Kathy Miller, M.D.     317-274-0920     kathmill@iupui.edu   
Contact: Kerry Bridges     317-274-2552     kdbridge@iupui.edu   

Community Regional Cancer Center         
Indianapolis, Indiana, 46256
Contact: Sumeet Bhatia, M.D.     317-621-7104       
Contact: Lisa McVicker, R.N.     317-621-7104

 Horizon Oncology Center (IN - Lafayette)
Lafayette, Indiana, 47905
Contact: Wael Harb, M.D.     765-446-5111     wharb@thecaregroup.com   
Contact: Linda Vaders, R.N.     765.446.5111     lvaders@thecaregroup.com  

Community Hospital, Monroe Medical Associates              
Munster, Indiana, 46321
Contact: Edwin Robin, M.D.     219-852-6456        
Contact: Mary Shields, R.N.     219.852.6456     mshields@comhs.org   

Northern Indiana Cancer Research Consortium    
South Bend, Indiana, 46601
Contact: Jose Bufill, M.D.     574-234-5123       
Contact: Susan Haithcox, R.N.     (574) 647-7977     shaithcox@memorialsb.org   

Missouri

Siteman Cancer Center
St. Louis, Missouri, 63110
Contact: Joel Picus, M.D.     314-747-1367       
Contact: Henry Robinson     314-747-1375     hrobinso@im.wustl.edu   

New Mexico
New Mexico Cancer Care Alliance
Albuquerque,New Mexico,87131
Contact: Kathy Anderson505-925-0405

Ohio

University Hospitals, Case Medical Center
Cleveland, Ohio, 44106
Contact: Tammy Kindwall-Keller, D.O.     216-844-5470       
Contact: Courtney McGuire     216.844.5470       

Pennsylvania

Bux-Mont Oncology Hematology Associates (FCCC) at Grand View Hospital
Fox Chase Cancer Center Extramural Research Program    Recruiting
Rockledge, Pennsylvania, 19046
Contact: Judi Seldomridge, RN     215-728-7413     J_Seldomridge@fccc.edu
or Pat Parsons(215) 257-6858

PinnacleHealth Fox Chase Regional Cancer Center
Harrisburg, Pennsylvania
Contact: Kathy Litchfield717-782-4750

Tennessee

ACORN: The West Clinic
Memphis, Tennessee, 38138
Contact: Beverly B. Fryar RN, 901-683-0055 x1075
bfryar@westclinic.com

Virginia

Virginia Oncology Associates
Norfolk, Virginia, 23502
Contact: Wendi Gobhardt, RN, BSN, OCN757-213-5813

 

Page updated 02/08/13

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org